MDXH: Q2 revenue up 16% YoY, losses widened, but 2026 guidance and positive EBITDA outlook reaffirmed
I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue grew 16% year-over-year to $27.2 million, with sequential gains and a strong recovery in tissue-based diagnostics. Operating losses widened due to ExoDx integration, but the company remains on track for 2026 revenue guidance and expects a return to positive adjustedriginal document: MDxHealth SA [MDXH] SEC 6-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue grew 16% year-over-year to $27.2 million, with sequential gains and a strong recovery in tissue-based diagnostics. Operating losses widened due to ExoDx integration, but the company remains on track for 2026 revenue guidance and expects a return to positive adjusted EBITDA.
Original document: MDxHealth SA [MDXH] SEC 6-K Current Report — Aug. 13 2026